


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in this Application:

**Listing of Claims:**

1. (Original) A phospholipidic preparation consisting in a release system and a lexitropsin of general formula I



in which R<sub>1</sub> is a functional group, preferably a basic one such as a simple or substituted amidine, a secondary or tertiary amine, a quaternary ammonium group, a simple or substituted guanidine, selected from:

-C(NH)NH<sub>2</sub>, -C(NH)NHR<sub>3</sub>, -NH<sub>2</sub>, NHR<sub>3</sub>, -N(R<sub>3</sub>)<sub>2</sub>, -NR<sub>3</sub>R<sub>4</sub>, -NH-C(NH)NH<sub>2</sub>, -NH-C(NH)NHR<sub>3</sub>, -N(CH<sub>2</sub>)<sub>4</sub>, N(R<sub>3</sub>)<sub>3</sub><sup>+</sup>


whereas R<sub>2</sub> represents an aliphatic, aromatic, or arylaliphatic acyclic group, also if substituted with atomic groups containing one or more heteroatoms such as atoms of oxygen, nitrogen, or R<sub>2</sub> represents a sequence of one or more residues of 1-methyl-4-aminopyrrole-2-carboxylic acid, acylated or not acylated at the N-terminus, also terminating with a residue of 1-methyl-4-carboxamidopyrrole-2-carboxylic acid or with a residue of analogue aminoacids derived from a heterocycle different from pyrrole selected from furane, imidazole, thiophene, thiazole, or derived from benzene, pyridine, a diazine, pyrimidine, substituted or not at the terminal amino group with an acyclic group, or containing, in place of the free or substituted amino group a carboxamido group, and R<sub>3</sub> or R<sub>4</sub> are equal or different lower alkyl groups C<sub>1</sub> to C<sub>4</sub>,

the release system being a liposome, a micelle, a nanoparticle, a phospholipidic complex or a supramolecular phospholipidic structure able to incorporate a compound of general structure I in stable and reversible form.

2. (Original) A preparation according to claim 1, in form of multilamellar liposomes, composed of phosphatidyl glycerol (PG), phosphatidyl choline (PC) and cholesterol (C) containing an entrapped lexitropsin of formula I in an amount comprised in the range 1-10 percent of the mass of the liposome.

3. (Currently amended) A preparation according to claim 1, in the form of phospholipidic ~~vesicles~~ vesicles composed ~~by~~ of polyethyleneglycol phosphatidylethanolamine (PEGPE), PG and partially hydrogenated egg phosphatidyl choline (PHEPC) containing 1-10 % by weight of a lexitropsin.


4. (Original) A preparation according to any one of claims 1-3, comprising distamycin (II) in the form of an organic or inorganic salt, preferably as the hydrochloride, as



the active ingredient.

## II

5. (Original) A preparation, according to any one of claims 1-3 comprising a compound X in the form of an organic or inorganic salt, preferably as the hydrochloride.



6. (Original) A topical preparation according to any one of claims 1-5, containing from 0.1 to 10% of active principle.
7. (Original) An Injectable preparation according to any one of claims 1-5 providing a dosage from 0.1 to 20 mg of a lexitropsin of general formula I, II or X per kg body weight.
8. (Original) The use of the preparations of claims 1-7 for the preparation of medicaments for the treatment of viral, or bacterial, or protozoarian infections.